花旗发表报告指，康哲药业上半年收入40亿元，按年增长10.8%，符合预期；纯利为9.32亿元，按年增长3.1%。销售费用比率下降至35.6%，研发费用增加92%至2.03亿元，原因是增加了对创新药物的投资。花旗指，集采的影响已逐渐消失，创新应该成为康哲药业的增长动力，预计未来三年将有超过10个产品获批。康哲药业亦致力拓展东南亚市场，目标于2027年达至收支平衡。花旗将康哲药业目标价由12.6港元上调至16.6港元，评级“买入”。
花旗发表报告指，康哲药业上半年收入40亿元，按年增长10.8%，符合预期；纯利为9.32亿元，按年增长3.1%。销售费用比率下降至35.6%，研发费用增加92%至2.03亿元，原因是增加了对创新药物的投资。花旗指，集采的影响已逐渐消失，创新应该成为康哲药业的增长动力，预计未来三年将有超过10个产品获批。康哲药业亦致力拓展东南亚市场，目标于2027年达至收支平衡。花旗将康哲药业目标价由12.6港元上调至16.6港元，评级“买入”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.